About Jasper Therapeutics, Inc.
https://jaspertherapeutics.comJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
CEO
Ronald A. Martell
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-04 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
UBS
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
ABINGWORTH LLP
Shares:5.63M
Value:$9.12M
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:2.67M
Value:$4.32M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:1.49M
Value:$2.42M
Summary
Showing Top 3 of 68
About Jasper Therapeutics, Inc.
https://jaspertherapeutics.comJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.17M ▼ | $-18.74M ▲ | 0% | $-1.13 ▲ | $-18.51M ▲ |
| Q2-2025 | $0 | $27.08M ▲ | $-26.72M ▼ | 0% | $-1.74 ▼ | $-26.82M ▼ |
| Q1-2025 | $0 | $21.8M ▼ | $-21.24M ▲ | 0% | $-1.41 ▲ | $-21.52M ▲ |
| Q4-2024 | $0 | $25.29M ▲ | $-24.32M ▼ | 0% | $-1.62 ▼ | $-25.04M ▼ |
| Q3-2024 | $0 | $19.89M | $-18.64M | 0% | $-1.24 | $-19.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $50.9M ▲ | $57.47M ▲ | $45.9M ▲ | $11.57M ▼ |
| Q2-2025 | $39.51M ▼ | $46.47M ▼ | $22.96M ▲ | $23.5M ▼ |
| Q1-2025 | $48.8M ▼ | $57.6M ▼ | $15.35M ▼ | $42.24M ▼ |
| Q4-2024 | $71.64M ▼ | $79.9M ▼ | $18.23M ▲ | $61.67M ▼ |
| Q3-2024 | $92.5M | $99.41M | $15.73M | $83.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.74M ▲ | $-17M ▼ | $0 ▼ | $28.39M ▲ | $11.39M ▲ | $-17M ▼ |
| Q2-2025 | $-26.72M ▼ | $-15.45M ▲ | $1K ▼ | $6.16M ▲ | $-9.29M ▲ | $-15.46M ▲ |
| Q1-2025 | $-21.24M ▲ | $-22.84M ▼ | $4K ▲ | $0 ▼ | $-22.84M ▼ | $-22.84M ▼ |
| Q4-2024 | $-24.32M ▼ | $-21.13M ▼ | $-76K ▲ | $345K ▲ | $-20.86M ▼ | $-21.23M ▼ |
| Q3-2024 | $-18.64M | $-14.05M | $-274K | $9K | $-14.32M | $-14.33M |
CEO
Ronald A. Martell
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-04 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
UBS
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
ABINGWORTH LLP
Shares:5.63M
Value:$9.12M
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:2.67M
Value:$4.32M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:1.49M
Value:$2.42M
Summary
Showing Top 3 of 68